Humanized CTLA-4 single chain antibody and human perforin path formed peptide P34 recombinant immunotoxin

A CTLA-4 and single-chain antibody technology, applied in the field of fusion proteins, can solve the problems of strong immunogenicity, high toxicity and side effects, and low internalization steps, and achieve the effect of weak antigenicity, low toxicity, and high potency
CN100443503CInactive Publication Date: 2008-12-17WEST CHINA HOSPITAL SICHUAN UNIV
5 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
WEST CHINA HOSPITAL SICHUAN UNIV
Publication Date
2008-12-17
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention relates to new recombinant humanized immunotoxin hS83-P34, which contains fusion protein comprising the antigen associated molecule of humanized cytotoxic T cell antigen 4 and human porforin channel forming active molecule. The immunotoxin of the present invention has strict targeting, less tendency of damaging health cell, less toxic side effect, no need of internalization and intracellular transport, high acting efficiency, less likelihood of generating corresponding antibody, weak immunogenicity and less tendency of generating drug resistance. It may be used in treating some tumors and autoimmune diseases and suppressing immunologic rejection reaction in organ transplantation.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to a new type of recombinant immunotoxin, in particular to an active small molecular fragment based on the antigen binding molecule of cytotoxic T cell antigen 4 (Cytotoxic T Lymphocyte Antigen 4, CTLA-4) and the channel of membrane active toxin. Recombinantly constructed fusion protein hS83-P34.

[0002] The present invention also relates to the nucleotide sequence and amino acid sequence of the immunotoxin.

[0003] The present invention also relates to a pharmaceutical composition comprising the recombinant immunotoxin. Background technique

[0004] According to the principle of mutual recognition between antigens and antibodies, cytokines, growth factors, hormones and receptors, molecules that can kill cells are connected with guiding molecules such as antibodies to construct immunotoxins, which can specifically kill cells and realize drug delivery. targeted therapy.

[0005] Humanized cytotoxic T cell antigen 4 (Cy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More